Latest Amgen Stories
THOUSAND OAKS, Calif., July 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of
PORTLAND, Oregon, July 21, 2014 /PRNewswire/ -- A new report by Allied Market Research titled, "Global biosimilars/follow-on-biologics market (types, applications and geography)
Analysis Shows Study Met Primary and All Secondary Endpoints THOUSAND OAKS, Calif., July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating
BANGALORE, India and CRANBURY, N.J., July 16, 2014 /PRNewswire/ -- Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics,
Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ --
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms.
SUNNYVALE, Calif., June 18, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the appointment
Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/
The Lung-MAP trial uses a multi-drug, targeted screening approach to match patients with promising new cancer treatments based on their unique tumor profiles BETHESDA, Md., June 16,
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.